Local Recurrence in Dcis Treated Predominantly Without Radiation

Kozul, Christina

doi:10.26226/m.631a4b817e215f5e7f38577c

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of independence did not seem to be related to the initial treatment options, such as radiotherapy and endocrine therapy. A hypothesis we had that breast tumours recurring after radiotherapy would be more likely to be non-clonal due to the DNA-damaging effects of RT was not supported by our data, although our power was limited (RT+/clonal: 12/62, RT+/non-clonal: 1/10) due to a relatively low proportion undergoing radiotherapy treatment (53).…”

Section: Discussioncontrasting

confidence: 57%

Predictive biomarkers of breast ductal carcinomain situmay underestimate the risk of recurrence due tode novoipsilateral breast carcinoma development

Kader,

Zethoven,

Mahale

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: Development of ipsilateral breast carcinoma following a diagnosis of breast ductal carcinoma in situ (DCIS) has been assumed to represent recurrence of the primary tumour. However, this may not be the case and it is important to know how often recurrences are new primary tumours to ensure appropriate individualised therapy. Experimental Design: Ipsilateral primary-recurrence pairs (n=78) were sequenced to test their clonal relatedness. Shared genetic events were identified from whole exome sequencing (n=54 pairs) using haplotype-specific copy number and phylogenetic analysis. The remaining pairs were sequenced by a targeted panel or low-coverage whole genome sequencing. We included 32 non-recurrent DCIS to compare the genetic profiles between recurrent and non-recurrent disease to develop a predictive biomarker. Results: We found that 14% of DCIS recurrences were non-clonal, indicative of a new breast carcinoma. Four chromosomal changes (5q, 11q, 17q and 20q) and TP53 mutation were enriched in clonal primaries compared with non-recurrent DCIS (p<0.05, Fisher exact test). The prognostic value of TP53 was validated in an independent cohort using immunohistochemistry (HR=3.1; 95% CI 1.3-7.8). Non-clonal DCIS primaries had a very similar genetic profile to non-recurrent DCIS, suggesting this subset of cases would be identified as being at low risk of recurrence using tumour-intrinsic markers. Conclusions: We have identified a substantial rate of new ipsilateral primary carcinomas after a diagnosis of DCIS. Our results suggest, as with invasive breast cancer, that if a recurrent tumour with an independent origin occurs, then the patient is at a high risk through the environment, the breast microenvironment and/or has a genetic predisposition. Importantly, the frequency of new primaries will influence the interpretation of findings in DCIS biomarker discovery studies as the true recurrence rate will be incorrect, affecting these efforts.

show abstract

Section: Discussioncontrasting

confidence: 57%